VivoSeq
Dermatology

Plaque Psoriasis

13

Pipeline Programs↗

14

Active Trials↗

9

Companies Involved↗

Plaque Psoriasis is an emerging landscape with 13 programs across 9 companies. The most active players are Oruka Therapeutics, Inc., Johnson & Johnson, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. 9 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

30/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

Oruka Therapeutics, Inc.

4 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

7 programs

Phase 3H

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

4 programs

Phase 3M

MC2 Therapeutics

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

6 of 8 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody225%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 44% of 18 pipeline programs.

Analysis

Trial Status

16

clinical trials

Active, not recruiting7 · 44%
Recruiting6 · 38%
Completed2 · 13%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")
Recruiting·Novartis logoNovartis·Preclinical·NCT06382051·502 enrolled
A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
Recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07474792·160 enrolled
The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)
Recruiting·AbbVie logoAbbVie·N/A·NCT07039110·700 enrolled
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT07116967·3,040 enrolled
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Dose-range Finding Study of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis
Recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07290569·160 enrolled
An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis
Recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07449702·240 enrolled
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06220604·731 enrolled
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06143878·774 enrolled
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06095102·311 enrolled
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06095115·684 enrolled
77242113PSO3006: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Ps
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06934226·752 enrolled
A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis
Active, not recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07090330·80 enrolled
A Randomized, Multicenter, Investigator-Blind Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Chinese Subjects With Plaque Psoriasis
Active, not recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT07357831·537 enrolled
SEC-HOPE: A Multicenter Retrospective Cohort Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Not yet recruiting·Novartis logoNovartis·N/A·NCT07683065·150 enrolled
A Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 3 Clinical Study To Evaluate The Efficacy and Safety Of Roflumilast Cream 0.3% (Zoryve®) in the Treatment of Plaque Psoriasis In China
Completed·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT06648772·190 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)